Fund Management Differs From Investing
Share
Martin Shkreli shares his perspective on the differences between being a good investor versus being a good fund manager, drawing from his personal experiences in hedge funds. He emphasizes that success in investing doesn't automatically translate to success in managing funds.
Key Points:
-
Fund Management vs Investment Skills:
- Being a good investor and being a good fund manager are "pretty different things"
- You can be a brilliant investor but fail at managing the actual business
- The business side requires growing assets and satisfying clients, which many good investors don't want to do
-
Hedge Fund Industry Challenges:
- Hedge funds have the shortest lifespan of financial businesses
- Of the top 10 hedge funds of all time, roughly 5 were shut down by regulatory intervention
- There's approximately a 10% chance of "going to jail" being a hedge fund manager
- Most top hedge funds from the 1990s don't exist today
-
Personal Investment Psychology:
- The hardest challenge is fighting "2 or 3 different demons that are psychologically based"
- Key struggle is avoiding the desire to double down when wrong
- Must accept being wrong 35-40% of the time, which most people can't handle
- The market constantly humbles you and challenges your opinions
-
Fund Management Reality:
- Investors don't want you learning these lessons with their money
- Need to have these skills before starting a fund
- Started his fund too early before mastering these psychological aspects
- Never made significant money from hedge funds despite having good investment ideas
-
Industry Evolution:
- Hedge funds were a very small asset class in the past ($50-100B total)
- Today's industry has grown significantly but faces more challenges
- Modern hedge funds require different skills than in the past
- The industry has become more institutionalized and regulated
08:48 - 09:14
Full video: 01:42:17MS
Martin Shkreli
Former hedge fund manager and pharmaceutical executive. Founded Retrophin and Turing Pharmaceuticals, gaining notoriety for increasing the price of Daraprim.
Convicted of securities fraud in 2017, sentenced to seven years in federal prison. Banned from the pharmaceutical industry and ordered to return $64.6 million in profits.